Headache News

DENVER — In this Healio video, Jessica Ailani, MD, explains that patient selection for clinical trials is not a one-size-fits-all process.

DENVER — Nerivio, a noninvasive digital therapeutic device, provided migraine pain relief within 2 hours in 67% of adults and 71% of adolescents, Alon Ironi said at the American Headache Society’s annual scientific meeting.

DENVER – Individuals who had migraine with aura were more likely to have atrial fibrillation compared with those who had a migraine without aura, a presenter said at the American Headache Society annual meeting.

DENVER — Treatment with Vyepti was associated with a sustained reduction in the frequency of episodic and chronic migraines over 6 months, researchers reported at the American Headache Society annual scientific meeting.

DENVER — Trudhesa nasal spray provided pain relief for up to three consecutive migraine attacks in an open-label, 52-week phase 3 trial, researchers said at the American Headache Society annual scientific meeting.

DENVER — Psychedelic use, specifically psilocybin, is effective in treating cluster headaches and migraines, Emmanuelle Schindler, MD, PhD, said at the American Headache Society annual scientific meeting.

DENVER — Monoclonal antibodies have shown promise as an emerging treatment for migraine, Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, said at the American Headache Society annual scientific meeting.

DENVER — Improvements are needed in the process to secure funding for migraine research, Rami Burstein, PhD, said at the American Headache Society annual scientific meeting.

TecTraum Inc. announced complete enrollment status for a clinical trial evaluating its pro2cool device, a noninvasive hypothermic therapy system for treating concussions.

The FDA has issued a complete response letter to Axsome Therapeutics Inc., in which the agency declined to move forward with a new drug application for AXS-07, an acute treatment for migraine.